Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial - Davies, C; Pan, H; Godwin, J; Gray, R; Arriagada, R; Raina, V; Abraham, M; Medeiros Alencar, V H; Badran, A; Bonfill, X (Lancet, 2013)
et al.